ReviewTranslational medicine @ UniSa2022
Abdominal Aortic Aneurysm: Natural History, Pathophysiology and Translational Perspectives.
Review in Translational medicine @ UniSa, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 19 citations in OpenAlex.
- MSCT Assessment of Perivascular Adipose Tissue and Visceral Fat Characteristics in Aortic, Iliac, and Lower Limb Aneurysms.Biomedicines · 2026Article
- CT-Centered Multimodality Imaging of Arterial Wall Fragility in Acute Aortic Syndromes: A Narrative Review of Imaging Markers and Clinical Implications.Journal of cardiovascular development and disease · 2026Review
- Smooth Muscle Cell Specific Activity of SGK-1 Alters Aortic Stiffness and Abdominal Aortic Aneurysm Growth.Journal of vascular diseases · 2026Article
- Plasma Proteome Signature for Leukocyte Telomere Length and Its Link to Abdominal Aortic Aneurysm.Journal of cellular and molecular medicine · 2026Article
- The Association Between Serum HMGB2 Levels and Abdominal Aortic Aneurysm in Males: Insights Into the HMGB2-TREM Pathway.Reviews in cardiovascular medicine · 2025Article
- Exploring Disparities in Atherosclerosis Comorbidity with Aortic Aneurysm.Biomedicines · 2025Review
- Comprehensive Bioinformatics Analysis Reveals the Role of Shared Cuproptosis- and Ferroptosis-Related DEG DLD in Abdominal Aortic Aneurysm.Journal of cellular and molecular medicine · 2025Article
- Review
- Recent Advances and Perspectives in Anesthesiology: Towards Artificial Intelligence-Based Applications.Journal of clinical medicine · 2024Article
- Current Prognostic Biomarkers for Abdominal Aortic Aneurysm: A Comprehensive Scoping Review of the Literature.Biomolecules · 2024Article
- Utility of multimodal molecular imaging in the diagnosis and decision-making in arterial diseases.Polish journal of radiology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An abdominal aortic aneurysm (AAA) is a degenerative pathology that affects the infrarenal segment of the aorta, leading to its progressive dilatation and eventually rupture. The infrarenal segment is involved in 80% of the aortic aneurisms, and represents alone 30% of all aneurysms. The natural history of the disease is characterized by the progressive increase of the aortic diameter associated with proportionally higher risk of rupture, particularly for cases with diameter greater than 5.5 cm. In case of rupture the mortality rate is very high, independently from the endovascular or surgical treatment. The most important risk factors are older age, smoking, hypertension, dyslipidemia, and family history of AAA. The most frequent form is "atherosclerotic", but infectious, collagen disease-related, immune dysregulation-related, and post-traumatic AAA have also been described. Albeit multiple pathogenetic hypotheses have been proposed, the role of metallo-proteinases in the degeneration of the aortic wall seem to play a central role. Early detection of AAA is crucial for the identification and treatment before the onset of potentially life-threatening complications. Moreover, the individual risk stratification is fundamental for the clinical management and follow-up. The growing knowledge about the pathophysiology of AAA has the potential to lead to significant translational advances. The challenge for the next years is to employ bioinformatic and genetic models, also based on artificial intelligence and machine learning approach, to develop novel screening methods and to stratify individuals at higher-risk or in the early stages of AAA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.